Utilizes machine learning and AI to improve drug development and precision medicine for various diseases.
BullFrog AI Holdings, Inc. operates as a digital biopharmaceutical company in the United States, specializing in artificial intelligence and machine learning (AI/ML) applications for medical and healthcare data analysis. Central to its offerings is the bfLEAP platform, leveraging AI/ML to analyze both preclinical and clinical datasets. This innovative platform is pivotal in advancing research and development efforts within the biopharmaceutical sector, aiming to enhance treatment strategies and patient outcomes across various medical conditions.
The company has established strategic licensing agreements with prominent instituutions such as George Washington University and Johns Hopkins University. These agreements grant BullFrog AI Holdings, Inc. rights to utilize cutting-edge technologies in therapeutic approaches. Specifically, partnerships include rights to use siRNA targeting Beta2-spectrin for treating diseases like hepatocellular carcinoma and obesity, and formulations of Mebendazole for combating cancer and neoplastic diseases. These collaborations underscore the company's commitment to integrating advanced scientific innovations into its AI-driven healthcare solutions.
Founded in 2017 and headquartered in Gaithersburg, Maryland, BullFrog AI Holdings, Inc. continues to pioneer advancements in digital biopharmaceuticals. With a focus on harnessing the power of AI/ML for transformative healthcare insights, the company remains dedicated to driving innovation in medical research and therapeutic development.